Kintor Pharmaceutical Limited’s IPO On The Hong Kong Stock Exchange

Slaughter and May, Hong Kong, advised the sole sponsor, the joint global coordinators, the joint bookrunners and the underwriters on the Hong Kong and U.S. law aspects of the global offering and listing of Kintor Pharmaceutical Limited.

Kintor Pharmaceutical raised approximately HK$1.75 billion (approximately US$224 million) before exercise of the over-allotment option. Huatai Financial Holdings (Hong Kong) Limited (Huatai) acted as the sole sponsor, and Huatai, UBS AG Hong Kong Branch (UBS) and China International Capital Corporation Hong Kong Securities Limited (CICC) acted as the joint global coordinators. Huatai, UBS, CICC, CMB International Capital Limited, China Renaissance Securities (Hong Kong) Limited, Haitong International Securities Company Limited, CCB International Capital Limited and China Everbright Securities (HK) Limited acted as the joint bookrunners. The listing application was granted pursuant to Chapter 18A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Kintor Pharmaceutical is a Chinese clinical-stage novel drug developer focused on the research and development of potential first-in-class and best-in-class drugs for prostate cancer, breast cancer and other androgen receptor-related diseases. The Company’s lead drug candidate, Proxalutamide, is undergoing phase III clinical trials in China and phase II clinical trials in the United States for metastatic castration-resistant prostate cancer, as well as clinical trials for breast cancer.

Slaughter and May’s team included Benita Yu (Picture), Partner, John Moore, Partner, Charlton Tse, Partner, Jianhao Zheng, Counsel, Edward Lau, Associate, Clare Tsang, Associate, Hilda Li, Associate and Anthony Sze, Associate.

Involved fees earner: Edward Lau – Slaughter and May; Hilda Li – Slaughter and May; John Moore – Slaughter and May; Anthony Sze – Slaughter and May; Clare Tsang – Slaughter and May; Charlton Tse – Slaughter and May; Benita Yu – Slaughter and May; Jianhao Zheng – Slaughter and May;

Law Firms: Slaughter and May;

Clients: CCB International; China Everbright Securities; China International Capital Corporation Limited (CICC); China Renaissance Securities Limited; CMB International Capital Limited; Huatai Financial Holdings Limited; UBS AG Hong Kong Branch;

Author: Michael Patrini